Physician profile
Daniel S Kessler
NPI 1952330391
$869.88
in general payments reported to CMS, 2019-2025
8 companies · $326 in 2025
The $326 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.52 · 2020: $16.39 · 2021: $81.03 · 2022: $175 · 2023: $14.57 · 2024: $218 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $558.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $243.17 | 2022-2025 | Clareon Panoptix Pro, Unity, Clareon |
| Bausch & Lomb Americas INC. | $209.46 | 2022-2025 | Envista Mx60 Iol, Envista Aspire Iol, Xiidra |
| Allergan, INC. | $159.95 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $102.84 | 2024-2025 | Xdemvy |
| Merck Sharp & Dohme LLC | $72.32 | 2021-2023 | Bridion |
| Aerie Pharmaceuticals, INC. | $36.30 | 2019-2020 | |
| Rayner Intraocular Lenses Limited | $27.23 | 2024 | Omidria |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.